Vomiting

Subscribe to Selected New Research on Vomiting

11661 relevant articles (1230 outcomes, 1435 trials/studies) found for this Disease

Description: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Also Known As:

Emesis

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Signs and Symptoms

Digestive Signs and Symptoms

Vomiting: 11661

Postoperative Nausea and Vomiting: 1652

Hematemesis: 241

Morning Sickness: 38

Anticipatory Vomiting: 15

Related Diseases

1.	Nausea
2.	Neoplasms (Cancer)
3.	Pain (Aches)
4.	Vomiting
5.	Postoperative Nausea and Vomiting (PONV)
836 Diseases and 9097 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Fujii, Yoshitaka: 17 articles (03/2005 - 01/2002)
2.	Navari, Rudolph M: 13 articles (12/2007 - 06/2002)
3.	Hesketh, Paul J: 12 articles (06/2008 - 05/2003)
4.	Tanaka, Hiroyoshi: 11 articles (01/2005 - 01/2002)
5.	Rudd, John A: 10 articles (02/2007 - 10/2002)
6.	Grunberg, Steven M: 10 articles (10/2005 - 11/2002)
7.	Herrstedt, J: 8 articles (05/2008 - 05/2001)
8.	Fujii, Y: 8 articles (03/2008 - 03/2000)
9.	Gralla, Richard J: 7 articles (08/2007 - 05/2003)
10.	Roila, Fausto: 7 articles (02/2007 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vomiting:

1.	Ondansetron (Zofran)FDA LinkGeneric 01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505)" 03/01/1996 - "The need for antiemetic rescue therapy (ondansetron 0.15 mg/kg intravenously after three episodes of emesis prior to discharge) was significantly greater in children who received placebo compared with the ondansetron 0.15 mg/kg study group (13% vs 0%, P < 0.05)" 12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron" 12/01/1997 - "MEASUREMENTS AND MAIN RESULTS: All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001)" 02/01/1997 - "RESULTS: During 0-24 h, the number of emetic episodes experienced was significantly greater (P = 0.048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0.039) with ondansetron (58%) than placebo (17%)" Get all the results and reference details, order at left...
2.	Cisplatin (Platino)FDA LinkGeneric 02/01/2000 - "All three agents were highly effective against cisplatin-induced acute and late vomiting and the results were statistically significant" 01/01/1992 - "Most patients (64%) experienced emesis if C[4h] was < 20 ng/ml, whereas emesis did not occur in any patient with C[4h] > 80 ng/ml. Among patients receiving very high dosages of cisplatin (> 95 mg/m2), comparable levels of systemic exposure were not totally effective in preventing emesis" 07/01/2002 - "As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by moderately emetogenic agents can be prevented in over 90% of cases" 05/01/1983 - "Good results have been achieved in patients not previously treated with cisplatin, but further studies are needed to determine its level of efficacy in patients who have experienced severe vomiting during earlier courses of cytotoxic therapy" 07/01/1988 - "These results indicate that high-dose MCP plus DPH are effective in preventing cisplatin-induced vomiting" Get all the results and reference details, order at left...
3.	Dexamethasone (Maxidex)FDA LinkGeneric 04/01/2008 - "A significant reduction in vomiting from 27% to 11% was achieved following the introduction of routine use of intravenous dexamethasone during surgery" 04/01/2003 - "RESULTS: Compared with placebo, dexamethasone significantly decreased the incidence of early and late vomiting (P < 0.05, P < 0.001 respectively)" 02/01/1995 - "Addition of dexamethasone significantly improved prevention of both acute and delayed emesis" 10/01/2000 - "CONCLUSION: Dexamethasone is clearly effective in protecting from emesis both in the acute and delayed phases, with emesis avoided in one patient out of six treated" 01/01/1998 - "Six patients in group D and 19 in group S experienced vomiting at least once within the 24-h postoperative period; dexamethasone was effective in reducing the overall incidence of vomiting from 63.3% to 20.0% (P < 0.01)" Get all the results and reference details, order at left...
4.	Metoclopramide (Reglan)FDA LinkGeneric 11/01/1989 - "There was a significant reduction in the number of episodes of vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001)" 11/01/1984 - "Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting." 01/01/1985 - "The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis" 12/01/1995 - "At this time, the reference treatment for emesis was metoclopramide and thus, phase III trials have been initially conducted with this comparative treatment" 03/01/1986 - "Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]" Get all the results and reference details, order at left...
5.	Granisetron (Kytril)FDA LinkGeneric 09/01/1997 - "The percentage of emesis-free patients was significantly greater in the 5- to 20-microg/kg granisetron groups than in the control and 2-microg/kg granisetron groups (18%, 23%, 68%, 78%, and 75% of patients receiving saline or granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg, respectively)" 08/01/2003 - "Additionally, incremental doses of granisetron (up to 9 mg) have been shown to be effective and well tolerated in patients with refractory emesis" 01/01/1994 - "The efficacy of Granisetron, a new and selective 5HT3-receptor-antagonist in the treatment of cytostatic induced emesis, was tested in the department of gynaecology and obstetrics of the University of Essen on 77 patients" 11/15/1995 - "However, the addition of corticosteroid to orally administered granisetron improved the control of delayed emesis" 10/01/2005 - "RESULTS: The proportion of patients with no vomiting episode in the 0--6 h interval after administration of study medication was higher in each granisetron treatment group (>90%) than in the placebo group (77%)" Get all the results and reference details, order at left...
6.	AntiemeticsIBA 03/01/2003 - "Radiation-induced emesis is an important secondary effect of this anticancer treatment and it represents one of the causes of therapy interruption and decay of life quality before the introduction of optimal control of radiation-induced emesis with new antiemetic drugs which ensure the continuance of radiotherapy and avoid time breaks, that could negatively influence the efficacy of anticancer treatment" 08/01/2008 - "Experimental data provide evidence for efficacy against a wide range of peripheral and central emetic stimuli and clinical trials confirm that neurokinin-1 antagonists have significantly higher efficacy against vomiting than all other antiemetics, with relative risk reductions of over 50%" 05/01/2003 - "Available data indicates that the 5-HT3-receptor antagonists are at least as good as conventional antiemetics in controlling delayed-onset emesis, and that their efficacy in this setting may be improved by the addition of a corticosteroid" 03/01/1987 - "Combination anti-emesis has further improved control rates and new schedules of currently available anti-emetics are now proving their worth" 06/01/2007 - "These findings further suggest that the least shrew can be utilized as a versatile and inexpensive small animal model to rapidly screen the efficacy of investigational antiemetics for the prevention of radiation-induced emesis." Get all the results and reference details, order at left...
7.	Serotonin (5 Hydroxytryptamine)IBA 04/01/1996 - "Furthermore, based on our improved knowledge of the role of 5-HT in emesis and gastrointestinal motility, the therapeutic potential of potent mixed 5-HT4 agonists--5-HT3 antagonists in the control of cytotoxic-drug-induced emesis and associated gut motor disturbances will be discussed" 06/01/2003 - "Combination therapy with a 5-hydroxytryptamine (5-HT3) receptor antagonist and a steroid preparation is effective for controlling acute vomiting" 02/01/2003 - "The introduction of serotonin 5-HT(3)-receptor antagonists into clinical practice allowed for a dramatic improvement in the management of vomiting" 12/01/2006 - "CONCLUSIONS: Laboratory studies provide additional evidence that serotonin and SP are involved primarily, though not exclusively, in acute and delayed vomiting, respectively." 01/01/2003 - "In an attempt to examine the background of SSRI-induced emesis, the present study aims to describe the role of 5-hydroxytryptamine (serotonin:5-HT) from the viewpoint of 5-HT release in the mouse-isolated ileum" Get all the results and reference details, order at left...
8.	Droperidol FDA LinkGeneric 05/01/1981 - "The results showed that the dose of droperidol used in this study was very effective in reducing vomiting in children 11 to 15 years of age" 05/01/1995 - "There was a significant reduction in the incidence of vomiting in the recovery room (1.4% vs 9.2%, P < 0.005) and in the day ward (9.4% vs 18.3%, P < 0.05) in patients receiving droperidol" 01/01/1992 - "Droperidol seems to be more effective in reducing severe vomiting" 01/01/1992 - "Droperidol was more effective in reducing severe vomiting" 09/01/2003 - "In controls, the incidence of vomiting was 24.4%; with droperidol 5 micro g, it was 23.2% (NNT compared with control, 82 [7 to -8.5]); with 15 micro g, it was 22.0% (NNT, 41 [6.5 to -9.6]); and with 50 micro g, it was 12% (NNT, 8.1 [4.2-142])" Get all the results and reference details, order at left...
9.	tropisetron (Navoban)IBA 01/01/1994 - "Tropisetron at doses of at least 0.20 mg/kg was significantly more effective in preventing vomiting than lower tropisetron doses or placebo, both in terms of treatment failure (> four vomits) (P = 0.015) and patient and investigator efficacy ratings (P = 0.04 for investigator rating; P = 0.035 for patient rating)" 08/01/2007 - "There was no difference in the efficacy of relieving acute vomiting between homemade tropisetron hydrochloride and Navoban (P>0.05)" 10/01/1994 - "Improved control of emesis also was observed over 4 consecutive days of follow-up in the tropisetron group" 02/01/1995 - "The role of Navoban for delayed emesis must be evaluated in future trials" 11/01/1994 - "In this study failures ( > 3 vomiting) were rescued with a second infusion of tropisetron (5-mg fixed dose)" Get all the results and reference details, order at left...
10.	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 11/01/1995 - "However, with the development of basic research on the mechanisms of vomiting, each 5-HT3 receptor antagonist has appeared to have different pharmacological actions and, subsequently, the difference in the clinical efficacy of each drug has been reported in Europe and USA" 07/01/2000 - "Studies have yielded conflicting results concerning the use of 5-HT3 receptor antagonists alone in delayed emesis" 06/01/1996 - "Further studies in animals have provided valuable information relating to the pathophysiology of emesis and the mechanism of action of 5-HT3 receptor antagonists" 02/01/1990 - "In view of the widespread use of the ferret in studies of emesis and particularly in the characterization of the antiemetic actions of 5-HT3 receptor antagonist, the opportunity is taken to assess the suitability of this species for studies of emesis" 06/01/2007 - "The Acute emesis has become well controlled by the emergence appearance of 5-HT3 receptor antagonist, but control of delayed emesis (DE) is insufficient" Get all the results and reference details, order at left...
2253 Drugs and Important Bio-Agents and 9849 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 05/01/2004 - "These drugs have dramatically improved prophylaxis of chemotherapy-induced emesis, particularly when used in combination with a corticosteroid" 11/01/1995 - "CONCLUSIONS: The combination of PNC + DXM is more efficacious than PNC + PLC in protection against highly emetogenic chemotherapy-induced vomiting." 11/01/1993 - "In fact, 70-80% of patients submitted to highly or moderately emetogenic drugs achieve complete protection against vomiting during the first cycle of chemotherapy" 03/01/1997 - "The three drug combination significantly improved complete control of acute and delayed emesis over successive chemotherapy cycles." 07/01/1996 - "This drug is a good protective against chemotherapy induce emesis and is very easy to administer." Get all the results and reference details, order at left...
2.	Acupressure (Shiatsu) 07/01/2006 - "Acupressure (two trials) and acupuncture (six trials) modalities were effective in reducing vomiting (P < .005); however, ETS (two trials) did not show significant effects in reducing the vomiting (P = .118) in children" 07/01/2004 - "This study suggests that acupressure on P6 point appears to be an effective adjunct maneuver in the course of emesis control." 05/01/2006 - "Korean hand acupressure stimulations (two trials) had the best impact on reducing vomiting" 01/01/2007 - "The cumulative incidence of vomiting at 24 h was 25% with acupressure and 61% in controls" 07/01/2006 - "Acupuncture had the greatest impact on reducing vomiting when compared with acupressure and ETS in children." Get all the results and reference details, order at left...
3.	Analgesia 10/01/2008 - "The duration of effective analgesia was longer (260 +/- 32.5 vs. 143 +/- 22.1 min, P < 0.005), the incidence of shivering (20% vs. 60%, P < 0.005) and vomiting (5% vs. 30%, P < 0.005) were lower in group SR10" 07/01/2008 - "Among patients receiving oral analgesia, 10 of 201(5%) experienced emesis, in contrast to 7 of 270 (2.6%) in the no oral analgesic group, (difference in proportions 2.4% [95% CI -1.1 to 6.5])" 07/01/2008 - "Patients with and without prior oral analgesia within 6 h of ED presentation were compared with respect to emesis and other post-sedation complications" 02/01/2007 - "Patients who underwent laparoscopy returned to full feeds faster (laparoscopic, 18.1 hours; right upper quadrant incision, 28.1 hours; and semicircumumbilical incision, 28.9 hours) (P < 0.05), required less analgesia (laparoscopic, 2.1 doses; right upper quadrant incision, 4.0 doses; and semicircumumbilical incision, 4.3 doses) (P < 0.05), and had less emesis (laparoscopic, 1.6 episodes; right upper quadrant incision, 2.9 episodes; and semicircumumbilical incision, 3.5 episodes) (P < 0.05), resulting in faster discharge (laparoscopic, 2.0 days; right upper quadrant incision, 3.1 days; and semicircumumbilical incision, 3.2 days) (P < 0.05)" 09/01/2006 - "There were significantly fewer number of emesis episodes and doses of analgesia given in the laparoscopic group" Get all the results and reference details, order at left...
4.	Tonsillectomy 04/01/2008 - "A significant reduction in paediatric post-tonsillectomy vomiting through audit." 04/01/2008 - "CONCLUSIONS: At-home use of ODT may prevent emesis in children during the first 3 days after tonsillectomy in children" 06/01/2005 - "CONCLUSION: Application of TEAS on sedated children is an easy, painless, reliable and effective method for the prophylaxis of postoperative retching and vomiting in pediatric tonsillectomy." 01/01/2005 - "Vomiting post tonsillectomy at the University Hospital of the West Indies." 01/01/2003 - "Routine use in four children would be expected to result in one less patient experiencing post-tonsillectomy emesis (RD = -0.25, CI95 = -0.37, -0.13; p = 0.00004)" Get all the results and reference details, order at left...
5.	Cesarean Section (Caesarean Section) 01/01/1985 - "These facts (author means) provide greater security for patients waiting for caesarean sections even of vomiting or aspiration occurs." 11/17/1979 - "Compared with placebo, both drugs were found to reduce vomiting in approximately half the patients who had undergone caesarean section" 10/01/1999 - "Nausea and vomiting during Caesarean section." 09/01/1999 - "Nausea and vomiting during caesarean section under spinal anaesthesia." 09/01/1998 - "Nausea, vomiting and safety assessments were performed during and after spinal anaesthesia for caesarean section" Get all the results and reference details, order at left...
282 Therapies and Procedures and 4040 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Vomiting

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1230 Outcomes
Top 200 Key Medications
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>